800 Victoria Sq, Suite 3500, PO Box 242, The Stock Exchange Twr, Montréal, QC
Year called to bar: 2004 (QC)
Pierre-Oliver Charlebois is a leading lawyer in the areas of environmental, mining, energy, climate change, and corporate social responsibility law. Pierre-Olivier is the leader of the Corporate Social Responsibility group. He also heads the Environmental, Energy and Climate Change group for the Quebec region. Pierre-Olivier advises clients on compliance with environmental laws and regulations. He participates in obtaining government authorizations needed to develop new industrial and energy projects. He also represents clients during environmental administrative, penal and civil litigation. His mining expertise encompasses environmental aspects involved in acquiring, restoring, and closing a mine. His expertise in climate change covers all aspects of the carbon market, specifically compliance with Canadian and Quebec legislation and developing carbon offsets. In energy law, he advises private and public energy providers working with biomass, hydroelectric and wind power on regulatory and commercial issues. In corporate social responsibility, Pierre-Olivier helps clients implement strategies and policies on Aboriginal, environmental, regulatory, and other aspects of corporate social responsibility.
Postmedia Network Inc. (Postmedia) completed the acquisition of Sun Media Corporation’s (Sun Media) English language newspapers and speciality publications, as well as digital properties including the Sun chain of dailies, consisting of The Toronto Sun, The Ottawa Sun, The Winnipeg Sun, The Calgary Sun and The Edmonton Sun, as well as The London Free Press and the free 24 Hours dailies in Toronto and Vancouver, from Quebecor Media Inc. (the Sun Media Acquisition).
Sagent Pharmaceuticals, Inc., a leader of specialty pharmaceutical products with an emphasis on the injectable market, completed its acquisition of Omega Laboratories Limited, a market leading specialty pharmaceutical company based in Montreal, for approximately US$85.3 million (C$95 million) in cash. The combination of Sagent and Omega creates a premier generic injectable company with a robust product portfolio, deep development pipeline and strong global presence.
